PLK1 and breast cancer: Notably, by using multiple breast cancer cell lines, we found that pharmacologically inhibiting Src using dasatinib led to the reduction of known APCCdh1 substrate Plk1 in a similar fashion as using MEK inhibitor PD032590145, which has been shown previously to inhibit Cdh1 N-terminal phosphorylation and to restore APCCdh1 function in melanoma cells8 (Fig. 8a, b and Supplementary Fig. 8a, b).